It seems a change of focus may be required. We are presenting at pretty much any and every convention or discussion on amr developments. Surely if we don't get at least some version of 327 through Phase 3 and to market then there comes a point where it is a waste of money presenting any more? Surely everyone interested knows of rce now and they are on PEW list and various others. Without a product that is approved for sale anywhere in the world Surely the presentation funds would be better spent pushing trials??
It seems 28 million and already a few million of new raise gone and to date we are still years away from being able to sell anything to recoup losses? I thought others were kidding with the cost estimates they were throwing out but surely phase 1 trials are the cheapest part of getting drug to market. Upcoming and current requirements to get approval are starting to look significant considering it has taken 35 million+ to get to current point?
I'm assuming they only raised 11 mil at huge discount this time due to lack of enthusiasm and results after previous raise at 1.30. Seemed fairly apparent they needed at least 30 mil again?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)